4.5 Review

Patient blood management during the COVID-19 pandemic: a narrative review

期刊

ANAESTHESIA
卷 75, 期 8, 页码 1105-1113

出版社

WILEY
DOI: 10.1111/anae.15095

关键词

anaemia; coagulation; coronavirus; COVID-19; patient blood management

资金

  1. Vifor Pharma
  2. Pharmacosmos
  3. Fisher and Paykel
  4. Massimo
  5. Hemosonics
  6. Hemonetics
  7. Vifor
  8. Fresenius Medical
  9. B.Braun Melsungen
  10. CSL Behring
  11. Swiss National Science Foundation, Berne, Switzerland
  12. Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland
  13. Swiss Foundation for Anesthesia Research, Zurich, Switzerland
  14. Vifor SA, Villars-sur-Glane, Switzerland
  15. Novo Nordisk Health Care AG, Zurich, Switzerland
  16. CSL Behring GmbH, Marburg, Germany
  17. LFB Biomedicaments, Courtaboeuf Cedex, France
  18. Octapharma AG, Lachen, Switzerland

向作者/读者索取更多资源

As COVID-19 disease escalates globally, optimising patient outcome during this catastrophic healthcare crisis is the number one priority. The principles of patient blood management are fundamental strategies to improve patient outcomes and should be given high priority in this crisis situation. The aim of this expert review is to provide clinicians and healthcare authorities with information regarding how to apply established principles of patient blood management during the COVID-19 pandemic. In particular, this review considers the impact of the COVID-19 pandemic on blood supply and specifies important aspects of donor management. We discuss how preventative and control measures implemented during the COVID-19 crisis could affect the prevalence of anaemia, and highlight issues regarding the diagnosis and treatment of anaemia in patients requiring elective or emergency surgery. In addition, we review aspects related to patient blood management of critically ill patients with known or suspected COVID-19, and discuss important alterations of the coagulation system in patients hospitalised due to COVID-19. Finally, we address special considerations pertaining to supply-demand and cost-benefit issues of patient blood management during the COVID-19 pandemic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据